Compare FN & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FN | PODD |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | Cayman Islands | United States |
| Employees | 16457 | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7B | 17.0B |
| IPO Year | 2007 | 2007 |
| Metric | FN | PODD |
|---|---|---|
| Price | $661.25 | $196.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 20 |
| Target Price | ★ $489.14 | $349.80 |
| AVG Volume (30 Days) | 626.4K | ★ 874.8K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.21 | N/A |
| EPS | ★ 5.77 | 3.48 |
| Revenue | ★ $3,419,327,000.00 | $2,708,100,000.00 |
| Revenue This Year | $36.87 | $24.59 |
| Revenue Next Year | $18.16 | $19.18 |
| P/E Ratio | $107.09 | ★ $57.22 |
| Revenue Growth | 18.60 | ★ 30.73 |
| 52 Week Low | $167.33 | $197.54 |
| 52 Week High | $634.59 | $354.88 |
| Indicator | FN | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 65.80 | 22.91 |
| Support Level | $429.50 | N/A |
| Resistance Level | N/A | $299.75 |
| Average True Range (ATR) | 42.17 | 6.96 |
| MACD | 10.59 | -0.67 |
| Stochastic Oscillator | 90.54 | 4.49 |
Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.